| TRG 1 | OR (95% CI)a | Downstaging | OR (95% CI)a | ||
---|---|---|---|---|---|---|
 | n | (%) | n | (%) | ||
Sex | ||||||
 Man | 13 | (26.0) | Reference | 34 | (70.8) | Reference |
 Woman | 7 | (26.9) | 1.67 (0.60–4.62) | 18 | (72.0) | 0.90 (0.21–3.88) |
Age (years) | ||||||
 < 55 | 5 | (29.4) | Reference | 12 | (70.6) | Reference |
 55–64 | 5 | (18.5) | 0.36 (0.10–1.27) | 14 | (56.0) | 0.37 (0.07–1.99) |
 65–74 | 6 | (31.6) | 1.01 (0.26–3.85) | 16 | (84.2) | 2.93 (0.40–21.37) |
 ≥ 75 | 4 | (30.8) | 0.85 (0.20–3.56) | 10 | (83.3) | 2.75 (0.34–22.48) |
Distance EAS (mm) | ||||||
 < 60 | 9 | (23.7) | Reference | 29 | (80.6) | Reference |
 ≥ 60 | 8 | (27.6) | 0.88 (0.30–2.55) | 17 | (58.6) | 0.12 (0.02–0.69) |
 Unknown | 3 | (33.3) | 1.026 (0.22–7.12) | 6 | (75.0) | 0.15 (0.01–2.43) |
cT | ||||||
 cT2 | 2 | (40.0) | Reference | 3 | (100.0) | - |
 cT3 | 17 | (27.0) | 0.29 (0.02–4.14) | 42 | (67.7) | - |
 cT4 | 1 | (12.5) | 0.29 (0.02–5.68) | 7 | (87.5) | - |
cN | ||||||
 cN0 | 4 | (33.3) | Reference | 8 | (66.7) | Reference |
 cN1 | 10 | (25.6) | 0.59 (0.16–2.23) | 25 | (67.6) | 0.39 (0.06–2.60) |
 cN2 | 6 | (24.0) | 0.77 (0.18–3.34) | 19 | (79.2) | 1.14 (0.17–7.82) |
MRF involvment | ||||||
 No | 6 | (17.7) | Reference | 31 | (79.5) | Reference |
 Yes | 14 | (33.3) | 0.34 (0.11–1.01) | 21 | (61.8) | 0.29 (0.07–1.18) |
Single dose intensity | ||||||
 2.1 | 3 | (18.8) | Reference | 12 | (80.0) | Reference |
 2.16 | 9 | (37.5) | 1.45 (0.36–5.84) | 15 | (62.5) | 0.16 (0.02–1.47) |
 ≥ 2.2 | 8 | (22.2) | 1.45 (0.39–5.38) | 25 | (73.5) | 1.14 (0.14–9.25) |